DETROIT, Dec. 17, 2025 — The Barbara Ann Karmanos Cancer Institute has appointed Khalil Choucair, M.D., MSc, to its Thoracic Oncology and Phase I Clinical Trials Multidisciplinary Teams. Dr. Choucair completed his hematology and oncology fellowship at Karmanos, where he served as chief fellow, and began seeing patients in July 2025 at Karmanos Cancer Center in Detroit and Karmanos Cancer Institute – Dearborn.
“Karmanos is an esteemed institution where some of the best minds are studying daily to find the best cancer therapies,” Dr. Choucair said. “Having the opportunity to continue my practice and research at Karmanos is a privilege, and I look forward to contributing to advancements that will benefit patients locally and beyond.”
Dr. Choucair treats esophageal cancer, lung cancer, mesothelioma, thymoma and thymic carcinoma. His research focuses on thoracic oncology biomarkers, small cell lung cancer therapies, precision and tumor-agnostic oncology, immune therapies and modulation, metabolomic–tumor microenvironment interactions in SCLC, biomarker development, and neuroendocrine tumor plasticity and evolution to SCLC. As a member of the Phase I team, he helps evaluate new drugs, therapies and combinations in early clinical trials conducted prior to FDA approval.
“Dr. Choucair has a passion for understanding thoracic diseases and advancing therapies,” said George Yoo, M.D., FACS, chief medical officer at Karmanos Cancer Hospital. “He has already contributed significantly to the Thoracic Oncology MDT, including planning the annual Lung Cancer Symposium.”
Dr. Choucair co-directed the 2025 Lung Cancer Symposium with Hirva Mamdani, M.D., leads education initiatives as an advisory board member for Karmanos’ Office of Cancer Research, Training and Education Coordination since 2023, and serves as a clinical assistant professor in the Department of Oncology at Wayne State University School of Medicine.
He completed a research fellowship in precision oncology clinical trials at the Eleanor N. Dana Cancer Center, University of Toledo. He earned a Master of Science in Experimental Medicine at McGill University, completed medical training at the American University of Beirut, and finished residency training at the University of Kansas, where he served as chief resident for Research Development. He has authored more than 30 peer-reviewed articles.
Dr. Choucair is a member of the American College of Physicians, the American Society of Clinical Oncology, the Michigan Society of Hematology and Oncology, and the Society for Immunotherapy of Cancer.
Dr. Choucair’s physician profile is available on the Karmanos website. To request an appointment, visit karmanos.org or call 1-800-KARMANOS (800-527-6266).
About the Barbara Ann Karmanos Cancer Institute
Karmanos Cancer Institute delivers cancer care, research and education across Michigan and northern Ohio. As part of McLaren Health Care and in partnership with Wayne State University School of Medicine, Karmanos is recognized by the National Cancer Institute with a comprehensive cancer center designation and offers access to clinical trials and specialty care through multiple network sites.
Leave a Reply